Repatha Cuts Heart Attack Risk 20% Over Standard Treatment

In part 1 of this roundtable, the expert panel defines high-risk melanoma as stage IIB, IIC, III or IV disease and discusses treatment options for patients in the adjuvant setting.

ORLANDO — Obexelimab bested placebo in reducing glucocorticoid toxicity at 52 weeks among a cohort of patients with IgG4-related disease, according to data presented at ACR …

To keep up with COPD research and care developments, the 2027 Global Initiative for Chronic Obstructive Lung Disease report features one new section and several updated/revised sections. Claus F. …

People with alcohol-associated hepatitis are more likely to die from the disease if they use cannabis. A large multinational study just published in Alcohol: Clinical and Experimental Research is …

A study of 352 Swedish women found that those who used birth control pills and later menopausal hormone therapy had fewer signs of small vessel disease, but the observational findings do not justify …

In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for …

US biotech major Amgen has announced results from a large real-world study showing that treatment with Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with …